Clinical Trials Logo

Hand Deformities, Congenital clinical trials

View clinical trials related to Hand Deformities, Congenital.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05528744 Recruiting - Genetic Disease Clinical Trials

Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome

Start date: August 27, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to establish a registry of individuals with confirmed or suspected Chopra-Amiel-Gordon Syndrome (CAGS) to learn more about the range of symptoms, changes in the structure of the brain seen on imaging, and learning difficulties that individuals with this disorder may experience. The investigators will obtain medical history, family history, MRI records, patient photographs, and genetic test results from individuals with confirmed or suspected CAGS. A subset of participants will also undergo a standardized neurobehavioral assessment. This data will be maintained on a secure research database. Sample collection will be offered to participants for the functional testing and the generation of iPSC cell lines, for neuronal reprogramming and phenotyping.

NCT ID: NCT04564430 Recruiting - Trigger Finger Clinical Trials

Clonidine for Tourniquet-related Pain in Children

CLOTCH
Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

This study is designed as a randomized, placebo-controlled, double-blinded, clinical trial with two parallel groups. This study investigates the association between a single dose of the drug, Clonidine, and the total amount of opioid administered under and 24 hours after surgery in children undergoing orthopedic limb surgery with the use of tourniquet. The investigators hypothesize that administration of clonidine to children undergoing limb surgery with the use of inflatable tourniquets would reduce post-procedural pain. This study is a pilot to obtain an effect size. Based on this the investigators will calculate a sample size for the main trial enabling us to reach a power of 0.8 with a significans level of 0.05.